News
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the Best Large Cap Value Stocks to Invest In. Analyst Courtney Breen of ...
Gilead Sciences, Inc. (NASDAQ:GILD) is one of Goldman Sachs’ top healthcare stock picks. On July 10, the company announced it ...
Gilead Sciences (GILD) stock slips as the company agrees to pay $202M to settle allegations that its HIV drug promotion ...
CHICAGO Attorney General Kwame Raoul, as part of a bipartisan coalition of 49 attorneys general, announced a $202 million multistate settlement agreement ...
The World Health Organization (WHO) has included Gilead Sciences' twice-yearly formulation of lenacapavir for pre-exposure ...
A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food ...
Massachusetts AG Campbell secures $1.6 million for the state's Medicaid in a settlement with Gilead over illegal kickbacks ...
Gilead Sciences will pay more than $200 million after admitting to a multi-year illegal kickback scheme that pushed its HIV drugs through lavish perks for prescribers. New York Attorney General ...
Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized plans to supply a long-acting HIV prevention drug to low-income countries, despite the ...
1d
Pharmaceutical Technology on MSNWHO endorses Gilead’s Yeztugo for HIV preventionWHO’s director general described the policy guidelines for Gilead’s twice-yearly drug as the “next best thing” in the absence of a vaccine.
2don MSN
The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...
Gilead Sciences (GILD) stock in focus as the company joins The Global Fund to expand access to lenacapavir, an HIV PrEP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results